Evidera: Market Access Consulting Services

With rigorous, evolving, and heterogeneous payer evaluation criteria, challenging price negotiations, and a dynamic competitive environment, manufacturers need to prepare their market access strategy early in the product life cycle and assess often to ensure optimal access. Evidera is ideally positioned to help you create evidence-optimized value strategies to achieve your product access, price and reimbursement goals. Our team brings …

Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

HTA, France, Update, Pharma Pricing

Update on the New HTA in France

At the World Pharma Pricing & Market Access Congress 2014,  Jean-Luc Harousseau, President, HAS, gave a presentation entitled  “Updates on the New HTA in France” Download the presentation to learn: HTA in France :  Reimbursement and Pricing Initial listing: From HAS guidance to CEPS pricing Actual benefit (SMR): reimbursement and co-payment level Clinical Added Value (ASMR) 2008 –2012 Prices of new …

Private Cord Blood Banks vs Public Health: Is it Time to Bury the Hatchet?

Can private cord blood banks ever work in synergy with public and national health services? Cord blood is the blood that remains in the placenta and umbilical cord after a baby is born. It is rich in stem cells, which can help to cure many life threatening diseases. The stem cells found in cord blood restore the function of the …

Vbook: How can the industry work with payers to ensure that the best treatments get to patients?

      Ensuring that your medicines get to the patients that need them involves dealing with clinicians, payers, HTA bodies and internal and external stakeholders. Just as you think you understand the rules of the game, they change. We asked a number of acknowledged thought leaders their view on the fundamental question confronting the industry: How can we work …

Guest Post: Rapid Effectiveness Assessment Process Could Shape HTA in Eastern Europe

This article was provided by Richard Staines of APM Health Europe from its coverage of the recent Health Technology Assessment World conference in London. A rapid European effectiveness assessment process comparing new drugs to standard of care could provide key data for local health technology assessment (HTA) in smaller European countries, experts have been told. However, Wim Goettsch, project leader …

Ebook: Top Market Access Services Required by Pharma

  Download the ebook here Pharmaceutical market access is not easy. It can seem fickle, lengthy and very complicated. Ensuring that your medicines get to the patients that need them involves dealing with clinicians, payers, HTA bodies and internal and external stakeholders. Just as you think you understand the rules of the game, they change. Value based pricing anyone? It …

Download ebook: Top challenges in HTA

    In today's austere times, payers are continuing to control escalating healthcare costs, relying on health technology assessment agencies in order to make purchasing decisions and effective use of funds.  HTA is an important part of evidence-based health decision-making in most EU countries with ever increasing demands for value demonstration proving your drugs are most beneficial to patients. This …

Oncology: A special case for HTA?

  At Pharma Pricing & Market Access Europe 2013, Martina Barwig, Head of HTA, Lilly Deutschland gave a presentation entitled “Oncology: A special case for HTA?” Download the presentation and learn: European market access case studies, lessons learned with AMNOG Developments in European Health Technology Assessment Patient relevant endpoints and surrogates Download presentation The 8th Annual Pharma Pricing and Market …